Pharmacological profiles of galantamine: The involvement of muscarinic receptor

Japanese Journal of Neuropsychopharmacology

Volumn 32, Issue 1, 2012, Pages 1-8

  Matsuda, Toshio ^a,b   Ago, Yukio ^a   Takuma, Kazuhiro ^a  

^a OSAKA UNIVERSITY   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Galantamine; Muscarinic receptor; Prepulse inhibition

Indexed keywords

GALANTAMINE; MUSCARINIC RECEPTOR;

REVIEW;

ACETYLCHOLINE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GALANTAMINE; HUMANS; MICE; RECEPTORS, MUSCARINIC;

EID: 84861408149     PISSN: 13402544     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Ago, Y., Koda, K., Ota, Y., Kita, Y., Fukuda, A., Takuma, K. and Matsuda, T. (2011a) Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses. Synapse, 65: 1373-1377.
2. Ago, Y., Koda, K., Takuma, K. and Matsuda, T. (2011b) Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci, 116: 6-17.
3. Allen, T. B. and McEvoy, J. P. (2002) Galantamine for treatment-resistant schizophrenia. Am J Psychiatry, 159: 1244-1245.
4. Almasieh, M., Zhou, Y., Kelly, M. E., Cassanove, C. and Di Polo, A. (2010) Structural and functional neuroprotection in glaucoma: Role of galantamine-mediated activation of muscarinic acetylcholine receptors. Cell Death Dis, 1: e27.
5. Arias, E., Alés, E., Gabilan, N. H., Cano-Abad, M. F., Villarroya, M., García, A. G. and López, M. G. (2004) Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: Involvement of nicotinic acetylcholine receptors. Neuropharmacology, 46: 103-114. (Pubitemid 37494744)
6. Auerbach, J. M. and Segal, M. (1994) A novel cholinergic induction of long-term potentiation in rat hippocampus. J Neurophysiol, 72: 2034-2040. (Pubitemid 24325121)
7. Autio, H., Mätlik, K., Rantamäki, T., Lindemann, L., Hoener, M. C., Chao, M., Arumäe, U. and Castrén, E. (2011) Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus. Neuropharmacology, 61: 1291-1296.
8. Bartus, R. T., Dean, R. L. 3rd, Beer, B. and Lippa, A. S. (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science, 217: 408-4014.
9. Bitsios, P., Giakoumaki, S. G., Theou, K. and Frangou, S. (2006) Increased prepulse inhibition of the acoustic startle response is associated with better strategy formation and execution times in healthy males. Neuropsychologia, 44: 2494-2499. (Pubitemid 44062565)
10. Bora, E., Veznedaroǧlu, B. and Kayahan, B. (2005) The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Pharmacol, 28: 139-141. (Pubitemid 40923414)
11. Bruel-Jungerman, E., Lucassen, P. J. and Francis, F. (2011) Cholinergic influences on cortical development and adult neurogenesis. Behav Brain Res, 221: 379-388.
12. Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M. and McMahon, R. P. (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry, 165: 82-89. (Pubitemid 351704556)
13. 7-containing nicotinic respetors promotes maturation and integration of adult-bom neurons in the hippocampus. J Neurosci, 30: 8734-8744.
14. Capsoni, S., Giannotta, S. and Cattaneo, A. (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA, 99: 12432-12437.
15. Crews, L. and Masliah, E. (2010) Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet, 19: R12-20.
16. Elgamal, S. and MacQueen, G. (2008) Galantamine as an adjunctive treatment in major depression. J Clin Psychopharmacol, 28: 357-359.
17. Fernández de Sevilla, D., Núñez, A., Borde, M., Malinow, R. and Buño, W. (2008) Cholinergic-mediated IP3-receptor activation induces long-lasting synaptic enhancement in CA1 pyramidal neurons. J Neurosci, 28: 1469-1478.
18. Fisher, A., Brandeis, R., Bar-Ner, R. H., Kliger-Spatz, M., Natan, N., Sonego, H., Marcovitch, I. and Pittel, Z. (2002) AF150 (S) and AF267B: M1 muscarinic agonists as innovative therapies for Altzheimer's disease. J Mol Neurosci, 19: 145-153. (Pubitemid 35013348)
19. French, S. J., Humby, T., Horner, C. H., Sofroniew, M. V. and Rattray, M. (1999) Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Brain Res Mol Brain Res, 67: 124-136. (Pubitemid 29170075)
20. Friedman, J. I. (2004) Cholinergic targets for cognitive enhancement in schizophrenia: Focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl), 174: 45-53.
21. Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., White, L., Parrella, M. and Davis, K. L. (2002) A double blind placebo controlled trail of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry, 51: 349-357. (Pubitemid 34251171)
22. Geyer, M. A., Krebs-Thomson, K., Braff, D. L. and Swerdlow, N. E. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl), 156: 117-154. (Pubitemid 32702206)
23. Gil-Bea, F. J., Solas, M., Mateos, L., Winblad, B., Ramírez, M. J. and Cedazo-Mínguez, A. (2011) Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. Hippocampus, in press.
24. Hajós, M. and Rogers, B. N. (2010) Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Curr Pharm Des, 16: 538-554.
25. 2 subunit of the neuronal nicotinic acetylcholine receptor. Synapse, 54: 200-206.
26. Hasselmo, M. E. and Sarter, M. (2010) Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology, 36: 52-73.
27. Haydar, S. N. and Dunlop, J. (2010) Neuronal nicotinic acetylcholine receptors - Targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Curr Top Med Chem, 10: 144-152.
28. Hernandez, C. M., Gearhart, D. A., Parikh, V., Hohnadel, E. J., Davis, L. W., Middlemore, M. L., Warsi, S. P., Waller, J. L. and Terry, A. V. Jr. (2006) Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Ther, 316: 679-694. (Pubitemid 43130995)
29. Hohnadel, E., Bouchard, K. and Terry, A. V. Jr. (2007) Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology, 52: 542-551. (Pubitemid 46123371)
30. Isoma, K., Ishikawa, M., Ohta, M., Ogawa, Y., Hasegawa, H., Kohda, T. and Kamei, J. (2002) Effects of T-82, a new quinoline derivative, on Cholinesterase activity and extracellular acetylcholine concentration in rat brain. Jpn J Pharmacol, 88: 206-212. (Pubitemid 34223571)
31. Itou, Y., Nochi, R., Kuribayashi, H., Saito, Y. and Hisatsune, T. (2011) Cholinergic activation of hippocampal neural stem cells in aged dentate gyrus. Hippocampus, 21: 446-459.
32. Jin, K., Xie, L., Mao, X. O. and Greenberg, D. A. (2006) Alzheimer's disease drugs promote neurogenesis. Brain Res, 1085: 183-188. (Pubitemid 43728188)
33. Kaasinen, V., Någren, K., Järvenpää, T., Roivainen, A., Yu, M., Oikonen, V., Kurki, T. and Rinne, J. O. (2002) Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol, 22: 615-620. (Pubitemid 35416788)
34. Kadir, A., Darreh-Shori, T., Almkvist, O., Wall, A., Grut, M., Strandberg, B., Ringheim, A., Eriksson, B., Blomquist, G., Långström, B. and Nordberg, A. (2008) PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging, 29: 1204-1217. (Pubitemid 351822413)
35. Kása, P., Rakonczay, Z. and Gulya, K. (1997) The cholinergic system in Alzheimer's disease. Prog Neurobiol, 52: 511-535. (Pubitemid 27405078)
36. Kawamata, J. and Shimohama, S. (2011) Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis, 24 [Suppl 21: 95-109.
37. Kesner, R. P. (1988) Reevaluation of the contribution of the basal forebrain cholinergic system to memory. Neurobiol Aging, 9: 609-616.
38. Kihara, T., Sawada, H., Nakamizo, T., Kanki, R., Yamashita, H., Maelicke, A. and Shimohama, S. (2004) Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. Biochem Biophys Res Commun, 325: 976-982. (Pubitemid 39487967)
39. Koda, K., Ago, Y., Kawasaki, T., Hashimoto, H., Baba, A. and Matsuda, T. (2008) Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl), 196: 293-301.
40. Koda, K., Ago, Y., Yano, K., Nishimura, M., Kobayashi, H., Fukada, A., Takuma, K. and Matsuda, T. (2011) Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation. Br J Pharmacol, 162: 763-772.
41. Kotani, S., Yamauchi, T., Teramoto, T. and Ogura, H. (2006) Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience, 142: 505-514. (Pubitemid 44415335)
42. Langmead, C. J., Watson, J. and Reavill, C. (2008) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther, 117: 232-243.
43. Lapchak, P. A., Araujo, D. M. and Hefti, F. (1993) Cholinergic regulation of hippocampal brain-derived neurotrophic factor mRNA expression: Evidence from lesion and chronic cholinergic drug treatment studies. Neuroscience, 52: 575-585. (Pubitemid 23058657)
44. Liu, Z. and Martin, L. J. (2006) The adult neural stem and progenitor cell niche is altered in amyotrophic lateral sclerosis mouse brain. J Comp Neurol, 497: 468-488. (Pubitemid 43865797)
45. Lorrio, S., Sobrado, M., Arias, E., Roda, J. M., García, A. G. and López, M. G. (2007) Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J Pharmacol Exp Ther, 322: 591-599. (Pubitemid 47105808)
46. Maelicke, A. and Albuquerque, E. X. (1996) New approach to drug therapy in Alzheimer's dementia. Drug Discov Today, 1: 53-59. (Pubitemid 126402341)
47. Maelicke, A., Schrattenholz, A., Samochocki, M., Radina, M. and Albuquerque, E. X. (2000) Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res, 113: 199-206. (Pubitemid 30645557)
48. Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X. and Zerlin, M. (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry, 49: 279-288. (Pubitemid 32178437)
49. Mann, K., Ackermann, K., Diehl, A., Ebert, D., Mundle, G., Nakovics, H., Reker, T., Richter, G., Schmidt, L. G., Driessen, M., Rettig, K., Opitz, K. and Croissant, B. (2006) Galantamine: A cholinergic patch in the treatment of alcoholism: A randomized, placebo-controlled trial. Psychopharmacology (Berl), 184: 115-121. (Pubitemid 43005764)
50. Mudo, G., Belluardo, N. and Fuxe, K. (2007) Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm, 114: 135-147. (Pubitemid 46018681)
51. Cognition and Dementia, 10 [Suppl 1]: 24-29.
52. Noda, Y., Mouri, A., Ando, Y., Waki, Y., Yamada, S. N., Yoshimi, A., Yamada, K., Ozaki, N., Wang, D. and Nabeshima, T. (2010) Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: Involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int J Neuropsychopharmacol, 13: 1343-1354.
53. 11C-nicotine binding in normal and Alzheimer brains - In vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord, 9: 21-27.
54. Oh, M. M., Wu, W. W., Power, J. M. and Disterhoft, J. F. (2006) Galantamine increases excitability of CA1 hippocampal pyramidal neurons. Neuroscience, 137: 113-123. (Pubitemid 43031479)
55. Ota, T., Shinotoh, H., Fukushi, K., Kikuchi, T., Sato, K., Tanaka, N., Shimada, H., Hirano, S., Miyoshi, M., Arai, H., Suhara, T. and Irie, T. (2010) Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. Clin Neuropharmacol, 33: 74-78.
56. Perry, E., Martin-Ruiz, C., Lee, M., Griffiths, M., Johnson, M., Piggott, M., Haroutunian, V., Buxbaum, J. D., Nãsland, J., Davis, K., Gotti, C., Clementi, F., Tzartos, S., Cohen, O., Soreq, H., Jaros, E., Perry, R., Ballard, C., McKeith, I., Court, J. (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol, 393: 215-222. (Pubitemid 30193419)
57. Rosse, R. B. and Deutsch, S. I. (2002) Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol, 25: 272-275. (Pubitemid 35239487)
58. Sarter, M., Parikh, V. and Howe, W. M. (2009) nAChR agonist-induced cognition enhancement: Integration of cognitive and neuronal mechanisms. Biochem Pharmacol, 78: 658-667.
59. Schilström, B., Ivanov, V. B., Wiker, C. and Svensson, T. H. (2007) Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology, 32: 43-53. (Pubitemid 44967783)
60. Schubert, M. H., Young, K. A. and Hicks, P. B. (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry, 60: 530-533. (Pubitemid 44402376)
61. Serres, F. and Carney, S. L. (2006) Nicotine regulates SH-SY5Y neuroblastoma cell proliferation through the release of brain-derived neurotrophic factor. Brain Res, 1101: 36-42. (Pubitemid 44055925)
62. Snape, M. F., Misra, A., Murray, T. K., De Souza, R. J., Williams, J. L., Cross, A. J. and Green, A. R. (1999) A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology, 38: 181-193. (Pubitemid 29073537)
63. Snorrason, E. and Stefánsson, J. G. (1991) Galanthamine hydrobromide in mania. Lancet, 337: 557.
64. Sweeney, J. E., Puttfarcken, P. S. and Coyle, J. T. (1989) Galanthamine, an acetylcholinesterase inhibitor: A time course of the effects on performance and neurochemical parameters in mice. Pharmacol Biochem Behav, 34: 129-137. (Pubitemid 20008895)
65. Swerdlow, N. R., Light, G. A., Cadenhead, K. S., Sprock, J., Hsieh, M. H. and Braff, D. L. (2006) Startle gating deficits in a large cohort of patients with schizophrenia: Relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry, 63: 1325-1335. (Pubitemid 44878517)
66. Takata, K., Kitamura, Y., Saeki, M., Terada, M., Kagitani, S., Kitamura, R., Fujikawa, Y., Maelicke, A., Tomimoto, H., Taniguchi, T. and Shimohama, S. (2010) Galantamine-induced amyloid-β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem, 285: 40180-40191.
67. Wadenberg, M. L. (2010) Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des, 16: 358-370.
68. Wadenberg, M. L., Fjällström, A. K., Federley, M., Persson, P. and Stenqvist, P. (2011) Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: Involvement of the cholinergic muscarinic receptor. Int J Neuropsychopharmacol, 14: 644-654.
69. Wang, D., Noda, Y., Zhou, Y., Nitta, A., Furukawa, H. and Nabeshima, T. (2007a) Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission. Neuropharmacology, 53: 379-389. (Pubitemid 47212249)
70. Wang, D., Noda, Y., Zhou, Y., Nitta, A., Furukawa, H. and Nabeshima, T. (2007b) Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model. Neuropharmacology, 52: 1179-1187.
71. Wang, Z. F., Tang, L. L., Yan, H., Wang, Y. J. and Tang, X. C. (2006) Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav, 83: 603-611. (Pubitemid 43817131)
72. Yanagida, T., Takeuchi, H., Kitamura, Y., Takata, K., Minamino, H., Shibaike, T., Tsushima, J., Kishimoto, K., Yasui, H., Taniguchi, T. and Shimohama, S. (2008) Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci Res, 62: 254-261.
73. Yano, K., Koda, K., Ago, Y., Kobayashi, H., Takuma, K. and Matsuda, T. (2009) Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br J Pharmacol, 156: 173-180.
74. Zhao, M., Momma, S., Delfani, K., Carlen, M., Cassidy, R. M., Johansson, C. B., Brismar, H., Shupliakov, O., Frisen, J. and Janson, A. M. (2003) Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA, 100: 7925-7930. (Pubitemid 36760071)